Newsroom
Sorted by: Latest
-
Samenvatting: FPT lanceert Flezi Foundry™, om AI-augmented levering te bevorderen voor internationale ondernemingen
HANOI, Vietnam--(BUSINESS WIRE)--Het internationale IT-bedrijf FPT kondigt de lancering aan van Flezi Foundry™ (FPT Digital Foundry™), een AI-augmented leveringsplatform voor softwareontwikkeling en IT-activiteiten. Dit platform, gebouwd rond een beheerd Service-as-a-Software model, combineert autonome AI agents, toezicht door menselijke experts, veilige infrastructuur en op resultaten gebaseerde leveringsmechanismen om ondernemingen te helpen de levering van technologie te moderniseren nu AI a...
-
Accord annonce un changement au sein de son conseil d'administration
TORONTO--(BUSINESS WIRE)--Accord Financial Corp. (TSX – ACD) a annoncé aujourd'hui la démission de M. David Spivak de son conseil d'administration. La société remercie M. Spivak pour sa contribution et lui souhaite beaucoup de succès dans ses futurs projets. À propos d'Accord Financial Corp. Accord Financial est l'une des sociétés de financement commercial les plus dynamiques du Canada. Elle offre des solutions de financement rapides et polyvalentes, notamment le financement sur actifs, l'affac...
-
TriCo Bancshares Announces Quarterly Cash Dividend
CHICO, Calif.--(BUSINESS WIRE)--The Board of Directors of TriCo Bancshares (NASDAQ: TCBK) (the “Company”), parent company of Tri Counties Bank, declared a quarterly cash dividend of $0.36 (thirty-six cents) per share on its common stock, no par value, on May 21, 2026. The dividend is payable on June 26, 2026, to holders of record as of June 5, 2026, and represents the 147th consecutive quarterly cash dividend paid to shareholders. Established in 1975, Tri Counties Bank is a wholly-owned subsidi...
-
INVESTOR ALERT: Securities Class Action Filed Against Veritone, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Veritone, Inc. (“Veritone” or the “Company”) (NASDAQ:VERI) securities during the period of October 14, 2025 through April 14, 2026, inclusive (“the Class Period”).If you suffered a loss on your Veritone investments, you have until July 20, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted aft...
-
Daten aus der zulassungsrelevanten Studie zu EP0031 (A400), einem selektiven RET-Inhibitor (SRI) der nächsten Generation, bei RET-positivem fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) werden auf der ASCO 2026 vorgestellt
LONDON--(BUSINESS WIRE)--Ellipses Pharma („Ellipses“), ein weltweit tätiges Unternehmen für die Entwicklung von Krebsmedikamenten mit einer Pipeline innovativer Programme, gab heute bekannt, dass sein Partner, Kelun-Biotech, auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) vom 29. Mai bis 2. Juni in Chicago Daten aus einer zulassungsrelevanten Studie zu EP0031/A400 für die potenzielle Behandlung von RET-Fusions-positivem nicht-kleinzelligem Lungenkrebs (NSCLC) vorstell...
-
Nuvve Announces Receipt of Nasdaq Notice on Late Filing of Its Form 10-Q
SAN DIEGO--(BUSINESS WIRE)--Nuvve Holding Corp. (“Nuvve”) (Nasdaq:NVVE), a global leader in advanced energy storage, grid modernization solutions and vehicle-to-grid (V2G) technology, today announced that it received written notice (the “Notice”) on May 22, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Report”), i...
-
Riassunto: I dati dello studio clinico pivotale di EP0031 (A400), un inibitore selettivo di nuova generazione della chinasi RET (Selective RET Inhibitor - SRI), nel NSCLC metastatico positivo alla fusione di RET, verranno presentati all'ASCO 2026
LONDRA--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), una società globale specializzata nello sviluppo di farmaci oncologici con una pipeline di programmi innovativi, ha annunciato oggi che il suo partner, Kelun-Biotech, sta presentando dati dallo studio clinico pivotale per EP0031/A400, per il potenziale trattamento del carcinoma polmonare non a piccole cellule (NSCLC) positivo alla fusione di RET, al Meeting annuale 2026 della American Society of Clinical Oncology (ASCO), che si terrà a Chic...
-
Resumen: Se presentarán en ASCO 2026 datos del estudio fundamental para EP0031 (A400), un inhibidor de RET selectivo (SRI) de próxima generación en NSCLC avanzado positivo para RET
LONDRES--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), una empresa de desarrollo de fármacos oncológicos global con una cartera de programas innovadores, anunció hoy que su socio, Kelun-Biotech, está presentando datos del estudio fundamental de EP0031/A400 para el potencial tratamiento de cáncer de pulmón de células no pequeñas (NSCLC) avanzado positivo para RET, en la reunión anual de la American Society of Clinical Oncology (ASCO) 2026, que se llevará a cabo en Chicago del 29 de mayo al 2 de...
-
Virta Health Notice of Data Event
DENVER--(BUSINESS WIRE)--Virta Health Corp. and Virta Medical PC (hereinafter, collectively “Virta Health”) is providing this substitute notice as a result of a security incident to provide individuals with information and to share resources available for those who wish to further safeguard their personal information. The privacy and protection of information is a top priority for Virta Health. On March 24, 2026, Virta Health identified unauthorized activity limited to a data repository that is...
-
